News
09.09.2025
GBAICTI, HKUMed and GSK signed the Tripartite Memorandum of Understanding
The Greater Bay Area International Clinical Trial Institute, the Department of Pharmacology and Pharmacy of the LKS Faculty of Medicine, The University of Hong Kong, and GSK signed a tripartite Memorandum of Understanding. The three parties jointly established a strategic framework to advance clinical data and real-world studies in the Greater Bay Area.
22.08.2025
GBAICTI and Bay Trial Advanced Collaborative Efforts in Strategic Meeting
GBAICTI and Bay Trial held a regular meeting to advance their collaborative platform, focusing on the practical implementation of talent exchange, joint branding, and knowledge-sharing initiatives to jointly promote clinical research development in the GBA.
19.08.2025
GBAICTI Showcased Hong Kong's Clinical Trial Strengths to Visiting Greater Bay Area Biomedical Delegation
GBAICTI presented Hong Kong's unique clinical trial advantages to a delegation of over 30 biomedical enterprise representatives from the Greater Bay Area, fostering cross-border collaboration in medical innovation.
12.08.2025
HKUMed, SMART and GBAICTI Met in Hong Kong to Foster Talent Exchange and Collaboration
On August 12, 2025, Prof. Bernard Cheung, CEO of GBAICTI, and Prof. CS Lau, Dean of HKUMed, met in Hong Kong with Prof. Nieng Yan, Founding President of Shenzhen Medical Academy of Research and Translation (SMART).
31.07.2025
GBAICTI Engaged With About 100 Industry Representatives to Enhance Hong Kong's Clinical Research Development
At a sharing session hosted by the Hospital Authority, the Greater Bay Area International Clinical Trial Institute (GBAICTI) engaged in-depth with around 100 industry representatives from over 30 companies to discuss enhancement measures and the future development of clinical trials in Hong Kong.
29.07.2025
GBAICTI, Bay Trial and Immuno Cure Signed Tripartite MOU to Strengthen GBA Clinical Research Collaboration
Greater Bay Area International Clinical Trial Institute, Greater Bay Area International Clinical Trials Center of Shenzhen and Immuno Cure BioTech signed a tripartite Memorandum of Understanding on July 29, 2025.